Gavi Alliance

TO SAVE LIVES & PROTECT PEOPLE'S HEALTH BY INCREASING EQUITABLE AND SUSTAINABLE USE OF VACCINES.

THE FIRST COVAX-SUPPLIED VACCINE DOSES WERE ADMINISTERED IN A GAVI COVAX AMC COUNTRY ON 16 JANUARY 2021. DURING 2021, 1.2 BILLION DOSES WERE MADE AVAILABLE BY MANUFACTURERS FOR DELIVERY, APPROXIMATELY 600 MILLION FROM DONATIONS AND 600 MILLION FROM APAS. OF THESE 1.2 BILLION DOSES, COVAX DELIVERED 946.6 MILLION DOSES FROM SEVEN MANUFACTURERS TO 144 COVAX PARTICIPANTS, JUST OVER 500 MILLION THROUGH APAS AND 435 MILLION THROUGH DOSE SHARING. OF THESE 946.6 MILLION DOSES, 829 MILLION DOSES WERE DELIVERED TO 86 AMC PARTICIPANTS; AND 116 MILLION DOSES WERE DELIVERED TO 58 SELF-FINANCING PARTICIPANTS (SFPS). AN ADDITIONAL 1.6 MILLION DOSES WERE DELIVERED TO COVAX HUMANITARIAN BUFFER RECIPIENTS IN 2021.BY END 2021, SUPPLY DELIVERED THROUGH COVAX ENABLED AMC91 (I.E. EXCLUDING INDIA) TO ACHIEVE 13% COVERAGE WITH AT LEAST ONE DOSE; AND 10% COVERAGE WITH TWO DOSES.REFLECTING ON THE ACHIEVEMENTS OF 2021, IT'S CLEAR MANY OF THE GAINS WERE HARD WON, AND IT TOOK MUCH LONGER TO ACHIEVE THE DELIVERY MILESTONES THAN ORIGINALLY ANTICIPATED. ALTHOUGH COVAX WAS UNABLE TO DELIVER ON ITS INITIAL DOSE DELIVERY GOALS, DELIVERING 829 MILLION VACCINE DOSES TO AMC ECONOMIES (AGAINST A TARGET OF 950 MILLION) WAS A TREMENDOUS ACHIEVEMENT. YET INEQUITIES BETWEEN AMC ECONOMIES AND HIGHER-INCOME COUNTRIES REMAINED AT THE END OF 2021. THE FOLLOWING LESSONS HAVE DRIVEN CHANGES TO COVAX'S OPERATIONAL MODEL AND WILL GUIDE OUR APPROACH TO THE GAVI COVAX AMC IN 2022.FURTHER INFORMATION ON GAVI'S COVAX REPORT CAN BE FOUND IN ITS 2021 ANNUAL PROGRESS REPORT, ONLINE AT: HTTPS://WWW.GAVI.ORG/PROGRAMMES-IMPACT/OUR-IMPACT/PROGRESS-REPORTS.

THE VACCINE GOAL: INTRODUCE AND SCALE UP VACCINESIN 2021, GAVI-SUPPORTED COUNTRIES ADMINISTERED MORE VACCINES THAN ANY YEAR IN HISTORY.GAVI SUPPORTED 39 VACCINE INTRODUCTIONS AND CAMPAIGNS THIS YEAR AN INCREASE FROM 21 IN 2020. THE 57 GAVI-SUPPORTED COUNTRIES HAVE INCREASED COVERAGE OF THREE KEY SDG VACCINES SINCE 2019.IN 2021, EMERGENCY STOCKPILES FOR CHOLERA, EBOLA, MENINGOCOCCAL AND YELLOW FEVER VACCINES WERE ACCESSED A TOTAL OF 25 TIMES BY 14 COUNTRIES.GAVI'S UPDATED MEASURE OF BREADTH OF PROTECTION, WHICH NOW INCLUDES COVERAGE AGAINST POLIO ANDHPV, REACHED 51% IN 2021, UP 16 PERCENTAGE POINTS FROM 2019.THE EQUITY GOAL: STRENGTHEN HEALTH SYSTEMS TO INCREASE EQUITY IN IMMUNIZATIONIN GAVI 5.0, HEALTH SYSTEM STRENGTHENING (HSS) SUPPORT PRIORITISES EQUITY IN IMMUNIZATION DELIVERY, TO REDUCE THE NUMBER OF ZERO-DOSE AND UNDER-IMMUNIZED CHILDREN.COVID-19 PANDEMIC-RELATED DISRUPTIONS TO ROUTINE IMMUNIZATION CONTINUED IN 2021, LEADING TO DECLINES IN COVERAGE IN GAVI-SUPPORTED COUNTRIES. OVERALL, THE RATE OF DECLINE IN IMMUNIZATION COVERAGE IN GAVI-SUPPORTED COUNTRIES SLOWED IN 2021 COMPARED TO THE DECLINE SEEN IN 2020.2021 SAW A RECORD NUMBER OF COLD CHAIN PROCUREMENTS THROUGH UNICEF, INCLUDING FROM GAVI'S CCEOP AND COVAX.IN 2021, 6.3 MILLION IMMUNIZATION SESSIONS WERE CONDUCTED IN GAVI-SUPPORTED COUNTRIES.IN 2021, DTP3 AND MCV1 COVERAGE IN GAVI-SUPPORTED COUNTRIES WAS 77% (COMPARED TO THE 81% GLOBAL AVERAGE) A DECLINE FROM 2020 OF 1 PERCENTAGE POINT FOR DTP3 AND 2 PERCENTAGE POINTS FOR MCV1.THE SUSTAINABILITY GOAL: IMPROVE SUSTAINABILITY OF NATIONAL IMMUNIZATION PROGRAMMESTHE YEAR 2021 CONFIRMED THE ROBUSTNESS OF THE VACCINE ALLIANCE'S CO-FINANCING APPROACH AND THE STEADY FINANCIAL COMMITMENT OF COUNTRIES DESPITE THE COVID-19 PANDEMIC.A TESTAMENT TO INCREASING COUNTRY OWNERSHIP AND THE LONG-TERM FINANCIAL SUSTAINABILITY OF GAVI-SUPPORTED VACCINES, COUNTRIES CONTRIBUTED A RECORD US$ 161 MILLION TOWARDS THE CO-FINANCING OF GAVI-SUPPORTED VACCINES IN 2021 DESPITE THE ONGOING FISCAL CHALLENGES OF THE COVID-19 PANDEMIC.THE NUMBER OF VACCINE PROGRAMMES ORIGINALLY INTRODUCED WITH GAVI FUNDING, BUT WHICH ARE NOW SELF-FINANCED BY COUNTRIES, INCREASED FROM 40 IN 2018 TO 49 IN 2020 AND 2021.IN A CHALLENGING FISCAL CONTEXT, MOST GAVI-ELIGIBLE COUNTRIES WERE ABLE TO MAINTAIN OR INCREASE DOMESTICRESOURCES FOR CO-FINANCING OF GAVI-SUPPORTED VACCINES IN 2021, BRINGING TO US$ 1.3 BILLION THEIR TOTAL CONTRIBUTION SINCE THE INTRODUCTION OF THE CO-FINANCING POLICY IN 2008.THE MARKET SHAPING GOAL: ENSURE HEALTHY MARKETS FOR VACCINES AND RELATED PRODUCTSGAVI'S MARKET SHAPING EFFORTS MAKE LIFE-SAVING VACCINES AND OTHER IMMUNIZATION PRODUCTS MORE ACCESSIBLE AND AFFORDABLE FOR LOWER-INCOME COUNTRIESIN 2021, THE NUMBER OF MARKETS EXHIBITING ACCEPTABLE LEVELS OF HEALTHY MARKET DYNAMICS FOR VACCINES AND IMMUNIZATION PRODUCTS IMPROVED FROM 10 TO 11, EXCEEDING THE TARGET FOR THE YEAR.INNOVATION-RELATED MARKET SHAPING INDICATORS ARE LARGELY ON TRACK. THE NUMBER OF INNOVATIVE PRODUCTS WITHIN THE PIPELINE OF COMMERCIAL-SCALE MANUFACTURERS INCREASED BY TWO IN 2021.THE GAVI BOARD APPROVED GAVI'S MARKET SHAPING STRATEGY FOR THE GAVI 5.0 STRATEGIC PERIOD (MSS 5.0); AND SUPPORT FOR MALARIA VACCINE ROLL-OUT IN SUB-SAHARAN AFRICA.THROUGH GAVI'S MARKET SHAPING EFFORTS, THE NUMBER OF MANUFACTURERS SUPPLYING PREQUALIFIED GAVI-SUPPORTED VACCINES HAS GROWN FROM 5 IN 2001 TO 18 IN 2021 (WITH MORE THAN HALF BASED IN AFRICA, ASIA AND LATIN AMERICA).FURTHER INFORMATION ON GAVI'S PROGRESS TOWARDS ACHIEVING ITS STRATEGIC GOALS CAN BE FOUND IN ITS 2021 ANNUAL PROGRESS REPORT, ONLINE AT: HTTPS://WWW.GAVI.ORG/PROGRAMMES-IMPACT/OUR-IMPACT/PROGRESS-REPORTS.